Expression of BARHL1 in medulloblastoma is associated with prolonged survival in mice and humans

J Pöschl1, A Lorenz, W Hartmann

  • 1Center for Neuropathology, Ludwig-Maximilians-University, Munich, Germany.

Oncogene
|May 24, 2011
PubMed

Insights

Barhl1 expression slows medulloblastoma growth. Loss of Barhl1 in mice and humans accelerates tumor progression and worsens prognosis, suggesting therapeutic potential for this transcription factor.

Area of Science:

  • Neuro-oncology
  • Developmental biology
  • Molecular oncology

Background:

  • Medulloblastoma is the most common pediatric malignant brain tumor.
  • Granule neuron precursors are implicated in medulloblastoma development.
  • The role of Barhl1 transcription factor in medulloblastoma is currently unknown.

Purpose of the Study:

  • To investigate the role of Barhl1 in medulloblastoma development and progression.
  • To determine the prognostic significance of Barhl1 expression in human medulloblastoma.

Main Methods:

  • Analysis of Barhl1 expression in human cerebellar development and medulloblastoma samples.
  • Generation and analysis of Barhl1 knockout mouse models for medulloblastoma.
  • Correlation of Barhl1 expression with patient survival data.

Main Results:

  • Barhl1 is upregulated during cerebellar development and in medulloblastoma.
  • Loss of Barhl1 in mice led to increased tumor cell proliferation and decreased neuronal differentiation.
  • Reduced Barhl1 expression in human medulloblastoma correlates with poorer patient prognosis.

Conclusions:

  • Barhl1 expression decelerates tumor growth in both human and mouse medulloblastomas.
  • Barhl1 may serve as a prognostic marker and a potential therapeutic target for medulloblastoma.